MedLink DiagnosticsJP
MedLink Diagnostics requires bridge financing to complete its PMDA regulatory submission and fund the final phase of clinical trials. A successful submission unlocks a $2M commercialisation grant from Japan's AMED agency. Seeking $100K debt bridge, repayable upon grant disbursement.
Risk Rating: Unrated
Risk assessment details are curated by our team.
Risk Score
30
High Risk
Opportunity Score
15
Moderate
Grand Score
45/100
High Risk
Revenue Stability
Max: 15 pts
Score: 8
Weighted: 8.00
Profitability
Max: 15 pts
Score: 8
Weighted: 8.00
Founder
Max: 15 pts
Score: 14
Weighted: 14.00
Industry
Max: 15 pts
Score: 8
Weighted: 8.00
Transparency
Max: 10 pts
Score: 8
Weighted: 8.00
Expansion Potential
Max: 7.5 pts
Score: 3
Scalability
Max: 7.5 pts
Score: 3
Market Size
Max: 7.5 pts
Score: 5
ROI Potential
Max: 7.5 pts
Score: 1
Full due diligence documents are available for verified Pro and Elite investors.
Listed on 3/31/2026